Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Argatroban - Generic Drug Details

« Back to Dashboard

What are the generic sources for argatroban and what is the scope of argatroban freedom to operate?

is the generic ingredient in four branded drugs marketed by Fresenius Kabi Usa, Hospira Inc, Mylan Institutional, Eagle Pharms, Sandoz, Hikma Pharm Co Ltd, Par Sterile Products, Teva Pharms Usa, and Pfizer, and is included in ten NDAs. There are three patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Argatroban has seven patent family members in five countries.

There are eleven drug master file entries for argatroban. Eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: argatroban

Drug Master File Entries: see list11
Suppliers / Packagers: see list8
Bulk Api Vendors: see list92
Clinical Trials: see list5
Patent Applications: see list5,395
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:argatroban at DailyMed

Pharmacology for Ingredient: argatroban

Tentative approvals for ARGATROBAN

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe250MG/250MLINJECTABLE; INJECTION
► Subscribe► Subscribe100MGINJECTABLE; INJECTION
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms
INJECTABLE;IV (INFUSION)022434-001Jun 29, 2011RXYesYes7,687,516► SubscribeY ► Subscribe
Mylan Institutional
INJECTABLE;INJECTION202626-001Jun 30, 2014APRXNoNo► Subscribe► Subscribe
Fresenius Kabi Usa
INJECTABLE;INJECTION201811-001Mar 23, 2015APRXNoNo► Subscribe► Subscribe
INJECTABLE;INJECTION020883-001Jun 30, 2000APRXYesYes► Subscribe► Subscribe
Eagle Pharms
INJECTABLE;IV (INFUSION)022434-001Jun 29, 2011RXYesYes7,589,106► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Formulary management
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus